§ 35-7-1802 — Definitions

(a) As used in this article:
(i) "Eligible patient" means a person who has:
(A) A terminal illness;
(B) Considered all other treatment options
currently approved by the United States food and drug
administration;
(C) Received a recommendation from a physician
for an investigational drug, biological product or device;
(D) Given written, informed consent for the use
of the investigational drug, biological product or device or, if
the patient is a minor or lacks the mental capacity to provide
informed consent, a parent or legal guardian has given written
informed consent on the patient's behalf; and
(E) Documentation from a physician that the
person meets the requirements of this paragraph.
(ii) "Investigational drug, biological product or
device" means a drug, biological product or device that has
successfully completed phase one of a clinical trial but has not
yet been approved for general use by the United States Food and
Drug Administration and remains under investigation in a
clinical trial;
(iii) "Terminal illness" means a disease that,
without life-sustaining procedures, will soon result in death or
a state of permanent unconsciousness from which recovery is
unlikely.